We import essential medicines to address shortages and meet market demands while strictly adhering to the MOH & Iran FDA regulations. Our portfolio covers critical therapeutic areas, including Metabolism and Endocrinology, Infectious Diseases, Oncology, Immunology, and Critical Care.
In addition, based on MOH requests, we introduce innovative pharmaceuticals not yet registered in Iran’s drug list (IDL), ensuring that patients have access to the latest treatments. Examples include Jakavi, Cabometyx, Zejula, and Blincyto.
As part of our expansion, we are entering the manufacturing sector, with a strategic focus on Endocrinology, Infectious Diseases, Oncology, and Critical Care. leveraging strong partnerships with both domestic and international suppliers.